Video
Author(s):
Key opinion leaders review the process of diagnosing HCC, the role of molecular testing, and associated challenges.
Durvalumab Plus Vaccine Therapy Elicits ‘Encouraging’ DFS in BCG-Unresponsive NMIBC
Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer
BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy
Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer
2 Commerce Drive
Cranbury, NJ 08512